Journal: iScience

Article Title: Human skin CD141 + dendritic cells regulate cutaneous immunity via the neuropeptide urocortin 2

doi: 10.1016/j.isci.2023.108029

Figure Lengend Snippet:

Article Snippet: The following antibodies were used in different combinations: CD3-FITC (eBioscience); CD19-FITC, CD20-FITC, CD56-FITC, CD25-PE, CCR4-PECy7, CCR6-PerCp/Cy5.5,HLA-ABC-PE, CD3 - BUV395 (BD); CLEC9A-PE, CD1c-PE, CD1c-APC, CD141-PE,CD141-APC, CD278 (ICOS)-VioGreen, CD127 – APC, CD25 -PE and CD45 -VioBright515 (Miltenyi); CD3-FITC, PD-L1-PE and CD45-PECy7 (eBioscience); CD11c-PerCp/Cy5.5, CD4 -BV785, CD8a - BV650, CTLA-4 - BV605, FoxP3 - BV421 and Ki-67 - BV711 (BioLegend); CCR10-PE (R&D Systems); CD14-FITC, CD83-FITC, CD86-FITC, CD40-FITC and HLA-DR-PE (Invitrogen).

Techniques: Purification, Recombinant, Staining, Concentration Assay, Sterility, Multiplex Assay, Labeling, Expressing, Transfection, Software

Journal: iScience

Article Title: Human skin CD141 + dendritic cells regulate cutaneous immunity via the neuropeptide urocortin 2

doi: 10.1016/j.isci.2023.108029

Figure Lengend Snippet:

Article Snippet: The following antibodies were used in different combinations: CD3-FITC (eBioscience); CD19-FITC, CD20-FITC, CD56-FITC, CD25-PE, CCR4-PECy7, CCR6-PerCp/Cy5.5,HLA-ABC-PE, CD3 - BUV395 (BD); CLEC9A-PE, CD1c-PE, CD1c-APC, CD141-PE,CD141-APC, CD278 (ICOS)-VioGreen, CD127 – APC, CD25 -PE and CD45 -VioBright515 (Miltenyi); CD3-FITC, PD-L1-PE and CD45-PECy7 (eBioscience); CD11c-PerCp/Cy5.5, CD4 -BV785, CD8a - BV650, CTLA-4 - BV605, FoxP3 - BV421 and Ki-67 - BV711 (BioLegend); CCR10-PE (R&D Systems); CD14-FITC, CD83-FITC, CD86-FITC, CD40-FITC and HLA-DR-PE (Invitrogen).

Techniques: Purification, Recombinant, Staining, Concentration Assay, Sterility, Multiplex Assay, Labeling, Expressing, Transfection, Software

Journal: iScience

Article Title: Human skin CD141 + dendritic cells regulate cutaneous immunity via the neuropeptide urocortin 2

doi: 10.1016/j.isci.2023.108029

Figure Lengend Snippet: UCN2 protects from alloimmune cell-mediated human skin inflammation in vivo (A) qPCR CRHR2 expression in cell populations isolated from human skin and blood, presented as arbitrary units (AU). (B) T cell suppression assay from sorted CD25 hi T cells from co-cultures with either CD1c + DDCs or CD141 + DDCs in the presence of vehicle control, CRHR2 antagonist (aCRHR2) alone, or together with UCN2 peptide. (C‒F) Experimental strategy to assess contribution of intradermally injected vehicle (PBS), aCRHR2 or UCN2 into human skin grafted NSG mice receiving intravenous PBS or allogeneic CD4 + T cells. Representative fields from stained skin grafts for (D) epidermal keratinocyte expression of the proliferation marker Ki67 (arrows), (E) epidermal CD3 + T cell infiltration (arrows), and (F) dermal FoxP3 + CD3 + T cells (arrows). Dashed lines indicate epidermal-dermal junction. Bars: 100μm. (G) Quantitative histological analysis of at least three independent visual fields per skin graft. Lines represent the mean ± SEM. (n = 3–6 animals per treatment group). Results are combined data from two independent experiments. One-way ANOVA test (B, G), ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 See also Figure S6 .

Article Snippet: The following antibodies were used in different combinations: CD3-FITC (eBioscience); CD19-FITC, CD20-FITC, CD56-FITC, CD25-PE, CCR4-PECy7, CCR6-PerCp/Cy5.5,HLA-ABC-PE, CD3 - BUV395 (BD); CLEC9A-PE, CD1c-PE, CD1c-APC, CD141-PE,CD141-APC, CD278 (ICOS)-VioGreen, CD127 – APC, CD25 -PE and CD45 -VioBright515 (Miltenyi); CD3-FITC, PD-L1-PE and CD45-PECy7 (eBioscience); CD11c-PerCp/Cy5.5, CD4 -BV785, CD8a - BV650, CTLA-4 - BV605, FoxP3 - BV421 and Ki-67 - BV711 (BioLegend); CCR10-PE (R&D Systems); CD14-FITC, CD83-FITC, CD86-FITC, CD40-FITC and HLA-DR-PE (Invitrogen).

Techniques: In Vivo, Expressing, Isolation, Suppression Assay, Injection, Staining, Marker

Journal: iScience

Article Title: Human skin CD141 + dendritic cells regulate cutaneous immunity via the neuropeptide urocortin 2

doi: 10.1016/j.isci.2023.108029

Figure Lengend Snippet:

Article Snippet: The following antibodies were used in different combinations: CD3-FITC (eBioscience); CD19-FITC, CD20-FITC, CD56-FITC, CD25-PE, CCR4-PECy7, CCR6-PerCp/Cy5.5,HLA-ABC-PE, CD3 - BUV395 (BD); CLEC9A-PE, CD1c-PE, CD1c-APC, CD141-PE,CD141-APC, CD278 (ICOS)-VioGreen, CD127 – APC, CD25 -PE and CD45 -VioBright515 (Miltenyi); CD3-FITC, PD-L1-PE and CD45-PECy7 (eBioscience); CD11c-PerCp/Cy5.5, CD4 -BV785, CD8a - BV650, CTLA-4 - BV605, FoxP3 - BV421 and Ki-67 - BV711 (BioLegend); CCR10-PE (R&D Systems); CD14-FITC, CD83-FITC, CD86-FITC, CD40-FITC and HLA-DR-PE (Invitrogen).

Techniques: Purification, Recombinant, Staining, Concentration Assay, Sterility, Reverse Transcription, Multiplex Assay, Labeling, Expressing, Transfection, Software